LOMAPT study

LO-MAPT: a study for the prevention of cognitive impairment in elderly people with a low DHA/EPA index in red blood cells

Aim

To demonstrate the efficiency of an 18-month intervention using omega-3 supplements (DHA+EPA) in the cognitive impairment in elderly people with a low DHA/EPA index in red blood cells and complaints of memory loss or a family history of Alzheimer’s Disease.

Methodology

The LO-MAPT study is a trial with two parallel groups, controlled by a placebo, in Phase 3 and randomised, with a duration of 18 months, which will be carried out three centres in two cities (two in Toulouse, France and one in Barcelona), followed by an extension phase where all participants receive a treatment containing omega-3.

The study is being led by Gérontopole and the Hospital of Toulouse, and the UAB Health and Ageing Foundation is responsible for the technical coordination.